Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Observer Blind Single-Coordinating Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX® When Given as Part of a Local Dosing Regimen in Infants

NCT01226953 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01226953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01226953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Observer Blind Single-Coordinating Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX® When Given as Part of a Local Dosing Regimen in Infants
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2010
Completion date
March 31, 2011
Enrollment
660 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilus influenzae type b (hib) infection